The international conference “New Approaches in Brain Tumors“, which saw the IRCCS Institute of Neurological Sciences of Bologna (ISNB) as a major protagonist. The event brought together national and international experts to discuss the latest advances in the diagnosis and treatment of brain tumorswith a particular focus on new therapeutic strategies and the multidisciplinary approach to treatment.
Among the topics covered during the congress, i new horizons in the molecular diagnostics phase and the new therapeutic perspectives with new generation drugs with targeted action. Furthermore, ample space was dedicated to non-pharmacological approaches such as focused ultrasoundthe new radiotherapy techniques and the cell therapieswhich represent future therapeutic strategies for brain tumor patients.
Il Doctor Enrico Franceschi, Director of the Nervous System Oncology Unit of the IRCCS ISNB and Chairman of the congressunderlined the importance of this meeting: “Brain tumors are a complex challenge, but the progress of recent years has allowed us to explore new therapeutic avenues. Today’s event confirmed how fundamental the collaboration between oncologists, neurosurgeons, radiation oncologists, pathologists and molecular biologists is to develop increasingly targeted and effective approaches. Multidisciplinarity is the key to improving the treatment prospects for our patients.”
Il Professor Raffaele Lodi, Scientific Director of IRCCS ISNBadded: “This conference confirmed how rapidly scientific research and technology are evolving to address the challenges of brain tumors. Thanks to the shared efforts of the scientific community, we are increasingly closer to personalized therapies that can respond specifically to the genetic characteristics of each tumor. Interdisciplinary collaboration is crucial to making progress and improving the quality of life of patients.”
The congress involved healthcare professionals from different disciplines, with sessions dedicated to crucial topics such as glioblastoma, low-grade gliomas and agnostic approaches for brain tumors. The active participation of the public and the lively debate generated by the interventions demonstrated the growing interest in the integration of new technologies and therapies within clinical practice.